Advanced Search

Journal of Traditional Chinese Medicine >

2025 , Vol. 45 >Issue 2: 443 - 449

DOI: https://doi.org/10.19852/j.cnki.jtcm.2025.02.019

Original articles

Efficacy of Jiedu formula (解毒方) as adjuvant therapy for early recurrence of hepatocellular carcinoma after radical surgery: a propensity score matching study

  • Qiuting FENG ,
  • Jiajia HU ,
  • Song YU ,
  • Huirong ZHU ,
  • Simo CHENG ,
  • Xiaofeng ZHAI
Expand
  • 1 School of Traditional Chinese Medicine, Naval Medical University, Shanghai 200433, China
    2 Oncology department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    3 Department of Oncology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received date: 2023-11-23

  Accepted date: 2024-06-22

  Online published: 2025-03-10

Supported by

Natural Science Foundation-funded Project: Mechanism of Action of Detoxification Formula to Inhibit Hypoxia-Inducible Factor 1 Alpha-Exosomal MicroRNA-130b-3p-Sterile Alpha Motif Domain-Containing Protein 90-mediated Macrophage M2-type Polarisation to Improve the Immunosuppressive Microenvironment in Hepatocellular Carcinoma(82374540);Medical Innovation Research Project of Shanghai Science and Technology Commission: a Multicenter Prospective Randomized Controlled Study of “Arsenic Target” Combination Therapy for Unresectable Hepatocellular Carcinoma(22Y11921200)

Fold

Abstract

OBJECTIVE: To investigate the clinical efficacy of using a Jiedu formula (解毒方) as an adjunctive therapy in patients with hepatocellular carcinoma (HCC) after hepatectomy.

METHODS: In total, 354 patients were included in this study. All patients were categorized into the traditional herbal medicine (THM) group (n =115) or the non-THM treatment (nTHM) group (n =239), with the Jiedu formula administered twice a day to the patients in the THM group. The primary outcome was recurrence-free survival (RFS). Univariate and multivariate Cox regression analyses were performed to identify the prognostic factors associated with RFS. Then, the high risk of recurrence among patients was identified, and propensity score matching (PSM) and RFS analysis were performed to analyze the prognostic factors for the outcomes of patients at a high risk of recurrence in different groups.

RESULTS: The one, two, three, and five-year RFS rates of the THM and nTHM groups were 76.4% vs66.1%, 65.5% vs48.8%, 57.9% vs39.9%, and 43.9% vs29.2%, respectively. The results of the Multivariate Cox analysis showed that giant tumors [hazard ratio (HR), 1.54, P = 0.04], poor degree of differentiation, microsatellite, or microvascular invasion (HR, 1.29, P= 0.09) increased the risk of recurrence. In the population with a high risk of recurrence, after PSM, the one, two, three, and five-year survival rates were 70.6% vs68.0%, 63.0% vs43.1%, 59.6% vs33.3%, and 41.9% vs26.4%, respectively.

CONCLUSION: In this study, THM was found to be an effective agent for adjuvant therapy for HCC to prevent early recurrence of HCC after hepatic resection.

Key words： carcinoma, hepatocellular; chemotherapy, adjuvant; propensity score; liver resection; Jiedu formula

Cite this article

Qiuting FENG , Jiajia HU , Song YU , Huirong ZHU , Simo CHENG , Xiaofeng ZHAI . Efficacy of Jiedu formula (解毒方) as adjuvant therapy for early recurrence of hepatocellular carcinoma after radical surgery: a propensity score matching study[J]. Journal of Traditional Chinese Medicine, 2025 , 45(2) : 443 -449 . DOI: 10.19852/j.cnki.jtcm.2025.02.019

References

1. Arndt V, Tim M, Gonzalo S, et al. Hepatocellular carcinoma. Lancet (London, England) 2022; 400: 1345-62.
2. Daniele AP, Tian Y, Vincenzo M, et al. Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg 2018; 268: 868-75.
3. Jordi B, Morris S. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.) 2011; 53: 1020-2.
4. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243: 229-35.
5. Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51: 890-7.
6. Fan ST, Poon RT, Yeung C, et al. Outcome after partial hepatectomy for hepatocellular cancer within the Milancriteria. Br J Surg 2011; 98: 1292-300.
7. Eguchi S, Kanematsu T, Arii S, et al. Liver cancer study group of Japan. recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011; 98: 552-7.
8. Lee KT, Wang SN, Su RW, et al. Is wider surgical margin justified for better clinical outcomes in patients with resectable hepatocellular carcinoma? J Formos Med Assoc 2012; 111: 160-70.
9. Zhang W, Zhang B, Chen Xp. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front. Med 2021; 15: 155-69.
10. Yu Y, Lang QB, Chen Z, et al. Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma. Chin Med J 2009; 122: 1990-95.
11. Yen CJ, Ai YL, Tsai HW, et al. Hepatitis B virus surface gene pre-S2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection. Hepatology 2018; 68: 815-26.
12. Yen CJ, Ai YL, Tsai HW, et al. A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021; 45: 101509.
13. Wang S, Zheng W, Zhang Z, et al. Microvascular invasion risk scores affect the estimation of early recurrence after resection in patients with hepatocellular carcinoma: a retrospective study. BMC Med Imaging 2022; 22: 204.
14. Wu JC, Huang TH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carci-noma. J Hepatol 2009; 51: 890-7.
15. Meng HN, Shen MQ, Li JJ, et al. Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis. Eur J Pharmacol 2021; 906: 174280.
16. Xia Z, Li M, Hu M, et al. Phosphoproteomics reveals that cinobufotalin promotes intrahepatic cholangiocarcinoma cell apoptosis by activating the ATM/CHK2/p 53 signaling pathway. Front Oncol 2022; 12: 982961.
17. Zhao HT, Meng YB, Zhai XF, et al. Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: a prospective multicenter cohort study. J Integr Med 2020; 18: 319-25.
18. Plessier A, Codes L, Consigny Y, et al. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 2004; 10: 86-90.
19. Qu LS, Liu JX, Zhu J, Lu CH. Risk factors for prognosis of hepatocellular carcinoma after curative resection in patients with low hepatitis B viral load. Ann Hepatol 2017; 16(3): 412-20.
20. Peng Y, Wu X, Zhang Y L, et al. An overview of traditional Chinese medicine in the treatment after radical resection of hepatocellular carcinoma. J Hepatocell Carcinoma 2023; 10: 2305-21.
21. Fan YQ, Ma Z, Zhao LL, et al. Anti-tumor activities and mechanisms of Traditional Chinese medicines formulas: A review. Biomed Pharmacother 2020; 132: 110820.
22. Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut 2018; 67: 2006-16.
Options
Outlines

/

〈 〉